Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing

KNI-272 is a human immunodeficiency virus (HIV) protease inhibitor with potent activity in vitro. We studied the pharmacokinetics of KNI-272 in the plasma and cerebrospinal fluid (CSF) of a nonhuman primate model and after intravenous and oral administration to children with HIV infection. Plasma an...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Mueller, Brigitta U., Anderson, Barry D., Farley, Maureen Q., Murphy, Robert, Zuckerman, Judy, Jarosinski, Paul, Godwin, Karen, McCully, Cindy L., Mitsuya, Hiroaki, Pizzo, Philip A., Balis, Frank M.
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 1998
Materias:	Antiviral Agents
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105689/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9661027/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.7.1815
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!